Form 8-K - Current report:
SEC Accession No. 0001193125-24-176312
Filing Date
2024-07-08
Accepted
2024-07-08 16:22:02
Documents
15
Period of Report
2024-07-08
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d863965d8k.htm   iXBRL 8-K 26201
2 EX-99.1 d863965dex991.htm EX-99.1 10790
6 GRAPHIC g863965g0707225347434.jpg GRAPHIC 3135
  Complete submission text file 0001193125-24-176312.txt   168349

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kymr-20240708.xsd EX-101.SCH 2852
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20240708_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20240708_pre.xml EX-101.PRE 11262
17 EXTRACTED XBRL INSTANCE DOCUMENT d863965d8k_htm.xml XML 3646
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 241104982
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)